A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with tacabrutideg in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.

Trial Details

NCT ID
NCT06634589
Phase
PHASE1 / PHASE2
Sponsor
BeOne Medicines
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Tacabrutideg
  • Sonrotoclax
  • Zanubrutinib
  • Mosunetuzumab
  • Glofitamab
  • Obinutuzumab
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Los Angeles, California, United States|34.05223,-118.24368
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Tampa, Florida, United States|27.94752,-82.45843
  • Westwood, Kansas, United States|39.04056,-94.6169

Key Eligibility Criteria

  • Must sign the informed consent form (ICF) and be capable of giving written informed consent, which includes compliance with the requirements and re…
  • Confirmed diagnosis of a R/R B-cell malignancy
  • Protocol-defined measurable disease
  • Stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →